MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Aldeyra Therapeutics Inc

Closed

2.65 9.05

Overview

Share price change

24h

Current

Min

2.37

Max

2.66

Key metrics

By Trading Economics

Income

-696K

-16M

Sales

245K

245K

EPS

-0.27

Profit margin

-6,465.066

Employees

9

EBITDA

-703K

-15M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+299.59% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-227M

134M

Previous open

-6.4

Previous close

2.65

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Aldeyra Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 lis 2024, 20:20 UTC

Major Market Movers

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Peer Comparison

Price change

Aldeyra Therapeutics Inc Forecast

Price Target

By TipRanks

299.59% upside

12 Months Forecast

Average 9.67 USD  299.59%

High 12 USD

Low 6 USD

Based on 7 Wall Street analysts offering 12 month price targets forAldeyra Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.935 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.